Wuxi KGBIO Biotechnology

KGbio (Kalbe Genexine Biologics) is a clinical-stage biotechnology company headquartered in Jakarta, Indonesia, focused on bringing innovative biologics and biosimilars to the Southeast Asian market and beyond. Established in 2016 as a joint venture between the Indonesian pharmaceutical giant Kalbe Farma and the South Korean biotech Genexine, the company has since attracted significant investment from global entities including WuXi Biologics and General Atlantic. KGbio's portfolio is centered on oncology and nephrology, featuring lead assets such as the PD-1 inhibitor Serplulimab and the long-acting erythropoietin Efepoetin alfa. The company utilizes advanced technology platforms like Genexine's hyFc for long-acting protein drugs and maintains a strategic manufacturing and development partnership with WuXi Biologics. By bridging the gap between global innovation and regional access, KGbio aims to become a leading biologics player in the ASEAN region.